[Pilomyxoid astrocytoma presenting in an elderly patient: a case report]

Keisuke Toyoda1, Keisuke Tsutsumi, Tomonori Ono

  • 1Department of Neurosurgery, National Nagasaki Medical Center, Japan.

Insights

This case report details an extremely rare instance of pilomyxoid astrocytoma (PMA) in a 77-year-old man. Further research is needed to establish treatment protocols for this rare adult brain tumor.

Area of Science:

  • Neuro-oncology
  • Pathology

Background:

  • Pilomyxoid astrocytoma (PMA) is a rare glioma, newly classified by the WHO in 2007.
  • PMA typically occurs in infants, with adult onset being exceptionally uncommon.

Observation:

  • A 77-year-old male presented with progressive visual disturbance and neurological symptoms.
  • MRI revealed a mass in the left basal cistern, sylvian fissure, and hypothalamus, causing ventricular enlargement.
  • Pathological diagnosis confirmed pilomyxoid astrocytoma (PMA) after open biopsy.

Findings:

  • The patient required a Ventriculoperitoneal shunt due to progressive hydrocephalus.
  • This represents one of the few reported adult cases of PMA, and the oldest at onset.
  • Symptoms in previously reported adult cases developed between the second and fourth decades of life.

Implications:

  • The extreme rarity of adult-onset PMA highlights the need for more case reporting and research.
  • Establishing effective treatment protocols for adult PMA requires further investigation and knowledge accumulation.
  • This case contributes valuable data to the understanding of rare adult brain tumors and their clinical presentation.

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...